Efficacy and safety of fremanezumab in patients with migraine and obesity: post-hoc analysis of the phase 3 HALO-LTS and FOCUS clinical trials

被引：0

作者：

Irimia Sieira, P. ^{[1
]}

Torphy, B. ^{[2
]}

Ortega, M. ^{[3
]}

Barash, S. ^{[3
]}

Krasenbaum, L. J. ^{[3
]}

Akcicek, H. ^{[4
]}

Smith, M. ^{[2
]}

Ning, X. ^{[3
]}

Campos, V. Ramirez ^{[3
]}

机构：

[1] Clin Univ Navarra, Neurol Dept, Pamplona, Spain

[2] Chicago Headache Ctr & Res Inst, Chicago, IL USA

[3] Teva Branded Pharmaceut Prod R&D Inc, W Chester, PA USA

[4] Teva Netherlands BV, Amsterdam, Netherlands

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P035

引用

页数：2